Top

Clinical Research in Cardiology

Published in:

01-04-2014 | Original Paper

The Th17/Treg imbalance in patients with cardiogenic shock

Authors: Maria del Rosario Espinoza Mora, Michael Böhm, Andreas Link

Published in: Clinical Research in Cardiology | Issue 4/2014

Abstract

Aims

Type 17 helper T (Th17) cells producing the proinflammatory signature cytokine interleukin (IL)-17 are conterregulated by regulatory T cells (Treg) producing anti-inflammatory cytokines like transforming growth factor (TGF)-β and interleukin-(IL)-10. An imbalance of the Th17/Treg-ratio toward Th17 cell subset was shown to be involved in plaque destabilization and acute myocardial infarction (AMI), while no data exist in infarction-related cardiogenic shock (CS). The objective of this study was to evaluate the role of Th17/Treg and their related cytokines in uncomplicated AMI and infarction-related CS.

Methods and results

In an observational monocentric study, blood sample from age-matched healthy controls (HC, n = 20), patients with uncomplicated AMI (n = 20), patients with CS who survived for at least 28 days (CS-survivors, n = 20) and CS-non-survivors (n = 20) were analyzed. Circulating Th17 and Treg cell subsets and their intracellular cytokine expression were measured by flow cytometry and associated with circulating proinflammatory Th17-derived cytokines IL-6, IL-17 and their anti-inflammatory Treg-derived cytokines TGF-β and IL-10 measured by enzyme immunoassay. According to the severity of ACS, CS-non-survivors showed the highest levels of Th17 (p < 0.001) and the lowest levels of Treg cells (p < 0.001) favoring a Th17/Treg imbalance toward the proinflammatory Th17 response (p < 0.001). Changes of T cell subsets were also associated with a proinflammatory cytokine expression measured by increased IL-6 (p < 0.001) and IL-17 levels (p < 0.001) and decreased TGF-β (p < 0.001) and IL-10 levels (p = 0.057). For the Th17/Treg-ratio at admission, a cut-off point of >0.33 had a sensitivity of 90 % and a specificity of 80 % to determine 28-day mortality in CS (confirmed by ROC analysis, area under the curve: 0.88 ± 0.06, p < 0.001). Th17/Treg-ratio >0.33 was observed to be an independent predictor for 1-year mortality in CS confirmed by Cox proportional hazard analysis (hazard ratio (HR): 4.31; 95 % confidence interval (CI) 1.44–12.93; p = 0.009).

Conclusion

The Th17/Treg imbalance toward a Th17 shift might represent a promising candidate as therapeutic target and risk indicator in cardiogenic shock.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695PubMedCrossRef

Caligiuri G, Paulsson G, Nicoletti A, Maseri A, Hansson GK (2000) Evidence for antigen-driven T-cell response in unstable angina. Circulation 102(10):1114–1119PubMedCrossRef

De Palma R, Del Galdo F, Abbate G, Chiariello M, Calabro R, Forte L et al (2006) Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 113(5):640–646PubMedCrossRef

Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G et al (2007) Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 50(15):1450–1458PubMedCrossRef

Mor A, Luboshits G, Planer D, Keren G, George J (2006) Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 27(21):2530–2537PubMedCrossRef

Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT et al (2008) The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 127(1):89–97PubMedCrossRef

Li Q, Wang Y, Chen K, Zhou Q, Wei W (2010) The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome. Biochem Biophys Res Commun 394(3):836–842PubMedCrossRef

Liuzzo G, Trotta F, Pedicino D (2013) Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J 34(8):556–559PubMedCrossRef

Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25high regulatory cells in human peripheral blood. J Immunol 167(3):1245–1253PubMed

10.

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061PubMedCrossRef

11.

Brusko TM, Putnam AL, Bluestone JA (2008) Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223:371–390PubMedCrossRef

12.

Hansen W, Westendorf AM, Buer J (2008) Regulatory T cells as targets for immunotherapy of autoimmunity and inflammation. Inflamm Allergy Drug Targets 7(4):217–223PubMedCrossRef

13.

Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z (2011) Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 10(12):744–755PubMedCrossRef

14.

Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8(4):345–350PubMedCrossRef

15.

Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S (2013) Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells 18(4):247–265PubMedCentralPubMedCrossRef

16.

Zhao Z, Wu Y, Cheng M, Ji Y, Yang X, Liu P et al (2011) Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 217(2):518–524PubMedCrossRef

17.

Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A et al (2009) Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119(10):1424–1432PubMedCentralPubMedCrossRef

18.

Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S et al (2013) Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 34(8):570–577PubMedCrossRef

19.

Barbi J, Pardoll D, Pan F (2013) Metabolic control of the Treg/Th17 axis. Immunol Rev 252(1):52–77PubMedCentralPubMedCrossRef

20.

(1985) The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med 312(14):932–6

21.

Idanpaan-Heikkila JE (1994) WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med 26(2):89–94PubMedCrossRef

22.

Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270(24):2957–2963PubMedCrossRef

23.

Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Shock investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341(9):625–634PubMedCrossRef

24.

Werdan K, Russ M, Buerke M, Delle-Karth G, Geppert A, Schondube FA (2012) Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German–Austrian S3 Guideline. Dtsch Arztebl Int 109(19):343–351PubMedCentralPubMed

25.

Selejan SR, Poss J, Hewera L, Kazakov A, Bohm M, Link A (2012) Role of receptor for advanced glycation end products in cardiogenic shock. Crit Care Med 40(5):1513–1522PubMedCrossRef

26.

Link A, Poss J, Rbah R, Barth C, Feth L, Selejan S et al (2013) Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J 34(22):1651–1662PubMedCrossRef

27.

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z et al (2006) Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27PubMedCrossRef

28.

Han SF, Liu P, Zhang W, Bu L, Shen M, Li H et al (2007) The opposite-direction modulation of CD4+CD25+Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol 124(1):90–97PubMedCrossRef

29.

Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ (2011) T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 32(9):395–401PubMedCentralPubMedCrossRef

30.

Taylor AW (2009) Review of the activation of TGF-beta in immunity. J Leukoc Biol 85(1):29–33PubMedCentralPubMedCrossRef

31.

Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P et al (2010) A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 185(10):5820–5827PubMedCrossRef

32.

Liao YH, Xia N, Zhou SF, Tang TT, Yan XX, Lv BJ et al (2012) Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol 59(4):420–429PubMedCentralPubMedCrossRef

33.

Zhu F, Wang Q, Guo C, Wang X, Cao X, Shi Y et al (2011) IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin Immunol 141(2):152–160PubMedCrossRef

34.

Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, Kanayama M et al (2012) Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arter Thromb Vasc Biol 32(2):273–280CrossRef

35.

Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O et al (2009) Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206(10):2067–2077PubMedCentralPubMedCrossRef

36.

Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE et al (2010) The relationship between CD4+CD25+CD127− regulatory T cells and inflammatory response and outcome during shock states. Crit Care 14(1):R19PubMedCentralPubMedCrossRef

37.

Hashmi S, Zeng QT (2006) Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 17(8):699–706PubMedCrossRef

38.

Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB et al (2008) Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5(4):e78PubMedCentralPubMedCrossRef

39.

Empana JP, Jouven X, Canoui-Poitrine F, Luc G, Tafflet M, Haas B et al (2010) C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the Prime study. Arter Thromb Vasc Biol 30(10):2047–2052CrossRef

40.

Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101(15):1767–1772PubMedCrossRef

41.

Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter JM et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38(1):152–160PubMedCrossRef

42.

Prondzinsky R, Unverzagt S, Lemm H, Wegener N, Heinroth K, Buerke U et al (2012) Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-gamma, TNF-alpha, MIP-1beta, G-CSF, and MCP-1beta. Med Klin Intensivmed Notfmed 107(6):476–484PubMedCrossRef

43.

Prondzinsky R, Unverzagt S, Lemm H, Wegener NA, Schlitt A, Heinroth KM et al (2012) Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol 101(5):375–384PubMedCrossRef

44.

Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG et al (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 44(2):340–348PubMedCrossRef

Title: The Th17/Treg imbalance in patients with cardiogenic shock
Authors: Maria del Rosario Espinoza Mora
Michael Böhm
Andreas Link
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 4/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0656-0

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Th17/Treg imbalance in patients with cardiogenic shock

Abstract

Aims

Methods and results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

The effects of exercise at high altitude on high-sensitivity cardiac troponin release and associated biventricular cardiac function

Successful management of cerebral embolism during TAVR

Possible spontaneous PFO closure after thrombus trapped in PFO

Epicardial ablation cures electrical storm caused by cardiac involvement in myotonic dystrophia type 2

Uncommon delayed and late complications after percutaneous left atrial appendage closure with Amplatzer® Cardiac Plug

Preinterventional screening of the TAVI patient: how to choose the suitable patient and the best procedure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page